Pagano E, Brunetti M, Tediosi F, Garattini L
Center for Health Economics CESAV, Mario Negri Institute for Pharmacological Research, Ranica, Italy.
Pharmacoeconomics. 1999 Jun;15(6):583-95. doi: 10.2165/00019053-199915060-00006.
To review studies on the costs of diabetes and its complications through a scheme designed specifically for assessing the quality of cost-of-illness (COI) studies.
The methodology of COI studies in diabetes was analysed in order to assess the significance of quantitative results. The scheme adopted 7 items identified as the main points for discussing the methodological choices governing the results. We also used a checklist based on questions related to the 7 items.
The answers showed that many studies appear not to give technical details, so it is hard to understand the method. Methodological choices varied widely between the studies. This is probably due to the lack of consensus on the methodology of COI studies. Based on the findings of this review, we suggest also some specific points that could help produce more reliable results on the costs of diabetes.
Clearly, a general consensus on COI studies is still remote, making the value of any comparison of results questionable.
通过专门设计用于评估疾病成本(COI)研究质量的方案,回顾有关糖尿病及其并发症成本的研究。
分析糖尿病领域COI研究的方法,以评估定量结果的重要性。该方案采用7项内容作为讨论影响结果的方法选择要点。我们还使用了基于与这7项内容相关问题的清单。
答案显示,许多研究似乎未给出技术细节,因此难以理解其方法。各项研究之间的方法选择差异很大。这可能是由于在COI研究方法上缺乏共识。基于本综述的结果,我们还提出了一些有助于得出更可靠的糖尿病成本结果的具体要点。
显然,在COI研究方面仍远未达成普遍共识,这使得任何结果比较的价值都值得怀疑。